news
Insilico and Qilu partner to create generative AI cardiometabolic drugs
Insilico Medicine and Qilu Pharmaceutical Group are expanding their existing R&D collaboration to apply generative AI to cardiometabolic drug discovery.
List view / Grid view
Cardiovascular disease
news
Beige fat identified as potential target for blood pressure drugs
New research shows beige fat around blood vessels helps regulate blood pressure, offering potential pathways for future therapies to reduce cardiovascular risk.
article
Beyond weight loss: the gap in current drug development for obesity
Current obesity drug development remains overly focused on short-term weight reduction, despite obesity being a chronic, multifactorial disease. Broader, mechanism-driven approaches are needed to ensure durable efficacy, safety and accessibility.
article
How real-world data is accelerating drug discovery
Vish Srivastava considers the benefits of expanding the role of real-world data in drug discovery to provide improved therapies, faster and with greater success.
article
Tracing ACLY from cardiovascular target to liver therapy lead
Can a cholesterol enzyme help treat an untreatable liver disease? Esperion’s ACLY programme is using multiomic and preclinical data to evaluate its potential in primary sclerosing cholangitis.
article
The rising impact of biomarkers in early clinical development
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
news
CNIC identifies key mechanism in fat cells to combat obesity
CNIC researchers have identified a mechanism in fat cells that helps them safely store excess fat, offering new insights for combating obesity and related metabolic diseases.
article
Cell and gene therapy development moves into cardiac indications
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
news
New agreement to progress cardiovascular disease research
The agreement between Cartherics, The University of Sydney and The University of Queensland will further stem cell-derived heart muscle therapy for heart failure.
article
The promise of therapeutics from molecules within our body
In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches.
article
Identifying vascular disease associations
In this Q&A, Associate Professor Dr Mete Civelek shares insights from the University of Virginia’s exciting recent study identifying several potential therapeutic targets for accelerating translational research in cardiovascular disease treatment, with a focus on proteins associated with the extracellular matrix (ECM) secretion by smooth muscle cells (SMCs).
news
Rare genetic variants found to have a large impact on obesity risk
Researchers have gained a deeper understanding of the neural biology of obesity, which could offer potential drug targets.
article
The first multi-chamber heart organoids developed
The first multi-chamber cardioids derived from hiPSCs have enabled scientists to investigate heart development and defects.
news
Are female mice better protected against obesity?
The University of California underwent a mouse study disclosing underlying sex differences in mice for obesity.
news
New treatment options for chronic kidney disease
Fresh insights from University of Edinburgh into a protein that causes damage in kidneys and hearts could open up new treatment options for chronic kidney disease.
